Methods
primary peritoneal cancer
FALLOPIAN TUBE
This multi-center, open-label, dose-escalation and PK-expansion phase 1 study (ClinicalTrials.gov, number NCT03075462) was conducted in 10 centers in China. Patients enrolled were women aged 18–70 years, had confirmed advanced high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (with or without gThe trial protocol was approved by the institutional review board or ethnic review committee of each participating center. All procedures were conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent before enrollment.